Search clinical trials for: Fc fusion protein

Total 25185 results

CytoDyn, Inc.
Amarex Clinical Research

No longer available

An Expanded Access Protocol for a Single Subject Who Has Completed 24-Weeks of Treatment in PR0140_CD02 Study (CD02_EA)

HIV

United States
Kevin F. Gibson
University of Pittsburgh

Terminated

Impact of Chemokine Receptor 5 (CCR5) Inhibition on Sarcoidosis Immunophenotypes (GRADS)

Sarcoidosis

United States
Centre hospitalier de l'Université de Montréal...
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

The Effects of the Direct Acting Antiviral Agent Boceprevir on the Pharmacokinetics of Maraviroc in Healthy Volunteers

Healthy

Canada
ViiV Healthcare
GlaxoSmithKline

Completed

A Phase 1 Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Infection, Human Immunodeficiency Virus

United States
University Of Perugia

Completed

Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients.

Inflammation | Atherosclerosis | Cardiovascular Risk Factor | HIV Infection With Other Conditions

Italy
SeaSpine, Inc.

Completed

Efficacy and Safety of Integra Accell Evo3 DBM in Instrumented Lumbar Spine Fusion

Spondylosis | Stenosis | Degenerative Changes

United States
Emory University

Terminated

Characterization and Modulation of Mucosal Immunity for HIV Prevention in Women (MIP)

HIV

United States
CSL Behring

Completed

An Observational Cohort Study of the Safety and Efficacy of Fibrinogen Concentrate, Human (FCH) in Subjects With Congenital Fibrinogen Deficiency

Congenital Fibrinogen Deficiency

United States, Canada
Dana-Farber Cancer Institute
Millennium Pharmaceuticals, Inc.

Completed

Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

Multiple Myeloma

United States
Boehringer Ingelheim

Completed

LUME-Ovar 1: Nintedanib (BIBF 1120) or Placebo in Combination With Paclitaxel and Carboplatin in First Line Treatment of Ovarian Cancer

Ovarian Neoplasms | Peritoneal Neoplasms

United States, Australia, Austria, Belgium, Canada, Czechia, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russian Federation, Slovakia, Spain, Sweden, Ukraine, United Kingdom
ViiV Healthcare
Pfizer

Completed

A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

HIV Coinfection

United States, Germany, Poland, Spain, Czechia, United Kingdom, Hungary, Puerto Rico, France
University of Lisbon

Completed

Exercise and Disease Progression in Amyotrophic Lateral Sclerosis Patients

Amyotrophic Lateral Sclerosis
THEVAX Genetics Vaccine
Clinical Research Management, Inc.

Unknown

Safety and Efficacy Study of TVGV-1 Vaccine to Treat HPV Induced Cervical HSIL

Human Papillomavirus | High-Grade Squamous Intraepithelial Lesions

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Drug-drug Interaction (DDI) Rifabutin

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Single-dose Pharmacokinetics of BMS-626529, Administered as BMS-663068, in Subjects With Hepatic Impairment Compared to Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

A Open-label, Drug-Drug Interaction With Maraviroc (DDI)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Bioavailability of BMS-626529 in Healthy Subjects From Prototype Low Dose Extended Release Formulations (Part 1) and Prototype Extended Release Multi-particulate Formulations (Part 2) of BMS-663068 Relative to 600 mg Extended Release Tablet

Infection, Human Immunodeficiency Virus

United Kingdom
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
International Partnership for Microbicides, Inc.
National Institute of Allergy and Infectious Diseases (NIAID); National Institutes...

Completed

Safety and Pharmacokinetic Study of Oral Maraviroc and Maraviroc 1% Gel in HIV-1 Seronegative Adults

HIV/AIDS

United States
Tianjin SinoBiotech Ltd.

Completed

Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

Cancer, Breast | Chemotherapy-induced Neutropenia

China
ViiV Healthcare
GlaxoSmithKline

Completed

A Study to Assess the Drug-drug Interaction of BMS 663068 With Methadone and Also With Buprenorphine/Naloxone

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

DDI Study of BMS-663068 With Etravirine (ETR) and/or Darunavir (DVR) + Ritonavir (RTV)

Infection, Human Immunodeficiency Virus
ViiV Healthcare
GlaxoSmithKline

Completed

A Drug-drug Interaction Study Between BMS-663068 and Oral Contraceptives in Healthy Female Volunteers (DDI)

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529

Infection, Human Immunodeficiency Virus

United States
ViiV Healthcare
GlaxoSmithKline

Completed

Absolute Bioavailability of BMS-626529 After Oral and Intravenous Dosing

Infection, Human Immunodeficiency Virus

United Kingdom
Tianjin SinoBiotech Ltd.

Completed

Study of Recombinant Human Serum Albumin/Granulocyte Colony-Stimulating Factor Fusion Protein

Chemotherapy-induced Neutropenia

China
Alphamab Jilin Co., Ltd.

Unknown

Single Dose Recombinant Human Follicle Stimulating Hormone Fc Husion Protein (KN015) in Healthy Volunteers

Infertility, Female

China
Hoffmann-La Roche

Terminated

A 48 Week Study Comparing Treatment With Saquinavir + Lopinavir/Ritonavir in Combination With Enfuvirtide HAART Versus Saquinavir + Lopinavir/Ritonavir + Other Nucleoside Combinations to See the Efficacy of These Treatments in Patients Infected With HIV-1

HIV Infection

United States
University of California, Davis

Completed

A Pilot Project of Virologic, Pharmacologic and Immunologic Correlates of Gastrointestinal-Associated Lymphoid Tissue Immune Reconstitution Following Maraviroc Therapy

HIV Infections

United States
ViiV Healthcare

Terminated

GW873140 In Combination With Combivir In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, France, Canada, Germany, Italy, Belgium, United Kingdom, Portugal, Spain
ViiV Healthcare

Terminated

GW873140 In Combination With Kaletra In HIV Infected Subjects

HIV Infection | Infection, Human Immunodeficiency Virus I

United States, Germany, France, Canada, Spain, Italy, Portugal, United Kingdom, Denmark, Netherlands
University of Sao Paulo

Completed

Taurine Supplementation and Triathletes

Athletic Proteinuria

Brazil
ViiV Healthcare

Completed

A Study of the Relative Bioavailability of BMS-626529 Administered as BMS-663068 From 150mg Low-dose Extended-release Tablets Compared to 600mg Reference Extended-release Tablets in Healthy Subjects

Infection, Human Immunodeficiency Virus

United States
Tianjin SinoBiotech Ltd.

Completed

Study of Recombinant Human Serum Albumin/Interferon alpha2b Fusion Protein in Chinese Healthy Volunteers

Healthy

China
Anhui Medical University

Unknown

High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs

Self Efficacy | Drug Toxicity

China
Amedica Corporation

Completed

Interbody Fusion Devices in the Treatment of Cervicobrachial Syndrome (CASCADE)

Myelopathy | Radiating Pain | Cervicobrachial Syndrome

Netherlands
CSL Behring

Completed

Study of the Pharmacokinetics and Safety of Recombinant Factor VIIa Fusion Protein (rVIIa-FP, CSL689) in Patients With Congenital Factor VII Deficiency

Congenital Coagulation Factor VII Deficiency

Netherlands, Norway
CSL Behring

Completed

A Safety and Pharmacokinetics Study of a Recombinant Fusion Protein Linking Coagulation Factor VIIa With Albumin (rVIIa-FP) in Healthy Male Volunteers

Healthy

Germany
ViiV Healthcare
Pfizer

Completed

THE EFFECT OF CYP3A5 GENOTYPE ON THE PHARMACOKINETICS OF MARAVIROC

Healthy Subjects

United States
Novartis Pharmaceuticals

Completed

Patient Preference Study of Pazopanib Versus Sunitinib in Advanced or Metastatic Kidney Cancer (PISCES)

Carcinoma, Renal Cell

France, Germany, Italy, United Kingdom, Finland
National Cancer Institute (NCI)

Terminated

Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers

Advanced Adult Primary Liver Cancer | Localized Unresectable Adult Primary Liver Cancer | Recurrent Adult Primary Liver Cancer | Recurrent Extrahepatic Bile Duct Cancer | Recurrent Gallbladder Cancer | Unresectable Extrahepatic Bile Duct Cancer | Unresectable Gallbladder Cancer | Cholangiocarcinoma... and other conditions

United States
National Center for Tumor Diseases, Heidelberg
University Hospital Heidelberg

Completed

CCR5-blockade in Metastatic Colorectal Cancer (MARACON)

Neoplasm Metastasis | Colorectal Cancer | Liver Metastases

Germany
University of Hawaii
Pfizer

Completed

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

HIV Infections

United States
California Cancer Consortium
National Cancer Institute (NCI)

Terminated

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

Kidney Cancer

United States
Drexel University
National Institute of Allergy and Infectious Diseases (NIAID)

Withdrawn

PRO 140 for Human Immunodeficiency Virus Infection

HIV

United States
Drexel University
National Institute on Drug Abuse (NIDA)

Withdrawn

PRO 140 for Human Immunodeficiency Virus

HIV

United States
CytoDyn, Inc.

Withdrawn

A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence

HIV

United States
DFINE Inc.

Withdrawn

Evaluation of Vertebral Compression Fracture Fixation With RF Kyphoplasty in Patients With Multiple Myeloma (MM)

Multiple Myeloma | Compression Fracture of Vertebral Column
Wake Forest University Health Sciences
National Cancer Institute (NCI)

Completed

DTGM Fusion Protein in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia

Leukemia

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Completed

Gefitinib in Treating Patients With Locally Advanced Esophageal Cancer

Esophageal Cancer

United States

Search clinical trials for: Fc fusion protein

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Australia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations